Oncopeptides AB (publ) Profit Margin

The latest profit margin for ONCO.ST is -696.66% as of March 2025. That compares with -627.53% in the prior-year period — down 11.0% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Oncopeptides AB (publ)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ONCO.ST's profit margin moved from -627.53% to -696.66% — a 11.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Oncopeptides AB (publ)'s valuation or profitability profile.

Against Healthcare companies, ONCO.ST currently prints -696.66% for profit margin, while the sector average sits near 9.48%. That is roughly 7448.0% below the sector mean. Large gaps often invite a closer look at Oncopeptides AB (publ)'s growth, margins, and balance sheet.

Profit Margin shows how effectively Oncopeptides AB (publ) converts resources into returns. At -696.66%, ONCO.ST may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -627.53% in the prior-year period — down 11.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ONCO.ST's profit margin (-696.66%), review year-over-year change from -627.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.